Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2
暂无分享,去创建一个
Y. Liu | M. Beal | N. Copeland | N. Jenkins | J. Troncoso | T. Dawson | V. Dawson | Lichuan Yang | Jaekwang Kim | J. McCaffery | Michael K. Lee | D. Galter | O. Pletnikova | D. Swing | B. Lin | D. Moore | Rebecca Banerjee | J. P. Daher | B. Thomas | Liliane Glauser | K. Stafa | D. Ramonet | M. Westerlund
[1] Richard Wade-Martins,et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. , 2009, Human molecular genetics.
[2] David W. Miller,et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.
[3] E. Tolosa,et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.
[4] C. Olanow,et al. Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants , 2007, Journal of neurochemistry.
[5] M. Geyer. The family of sensorimotor gating disorders: Comorbidities or diagnostic overlaps? , 2006, Neurotoxicity Research.
[6] T. Gasser. Mendelian forms of Parkinson's disease. , 2009, Biochimica et biophysica acta.
[7] R. Burke,et al. Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease , 2009, Nature Neuroscience.
[8] T. Dawson,et al. Value of genetic models in understanding the cause and mechanisms of Parkinson’s disease , 2008, Current neurology and neuroscience reports.
[9] T. Dawson,et al. Parkin mediates the degradation‐independent ubiquitination of Hsp70 , 2008, Journal of neurochemistry.
[10] T. Katada,et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. , 2007, Biochemistry.
[11] Sara Cipolat,et al. OPA1 Controls Apoptotic Cristae Remodeling Independently from Mitochondrial Fusion , 2006, Cell.
[12] M. Cookson,et al. LRRK2 Modulates Vulnerability to Mitochondrial Dysfunction in Caenorhabditis elegans , 2009, The Journal of Neuroscience.
[13] Irene Litvan,et al. Lrrk2 and Lewy body disease , 2006, Annals of neurology.
[14] H. Guo,et al. Improved neuronal transgene expression from an AAV‐2 vector with a hybrid CMV enhancer/PDGF‐β promoter , 2005, The journal of gene medicine.
[15] H. Cai,et al. The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2 , 2008, The Journal of Neuroscience.
[16] L. Petrucelli,et al. Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease , 2010, Nature Medicine.
[17] O. Sydow,et al. LRRK2 expression linked to dopamine‐innervated areas , 2006, Annals of neurology.
[18] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[19] H. Cai,et al. Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein , 2009, Neuron.
[20] K. Lim,et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.
[21] M. Cookson,et al. Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.
[22] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[23] P. Aebischer,et al. A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2 , 2011, The Journal of Neuroscience.
[24] Naoki Hisamoto,et al. LRK-1, a C. elegans PARK8-Related Kinase, Regulates Axonal-Dendritic Polarity of SV Proteins , 2007, Current Biology.
[25] C. Ross,et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] M V Ovanesov,et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia , 2008, Molecular Psychiatry.
[27] C. Ross,et al. A Drosophila model for LRRK2-linked parkinsonism , 2008, Proceedings of the National Academy of Sciences.
[28] R. J. Kelleher,et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice , 2010, Proceedings of the National Academy of Sciences.
[29] C. Ross,et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.
[30] Christine Klein,et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.
[31] D. Borchelt,et al. Amyloid Pathology Is Associated with Progressive Monoaminergic Neurodegeneration in a Transgenic Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.
[32] K. Lim,et al. Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila , 2009, The Journal of Neuroscience.
[33] J. Trojanowski,et al. Biochemical and pathological characterization of Lrrk2 , 2006, Annals of neurology.
[34] M. Cookson,et al. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. , 2007, Biochemical and biophysical research communications.
[35] Andrew B West,et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] Kazuko Hasegawa,et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family , 2005, Annals of neurology.
[37] T. Dawson,et al. Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons , 2009, Molecular Neurodegeneration.
[38] I. Marín. The Parkinson disease gene LRRK2: evolutionary and structural insights. , 2006, Molecular biology and evolution.
[39] P. Emson,et al. Localization of Parkinson’s disease-associated LRRK2 in normal and pathological human brain , 2007, Brain Research.
[40] P. Emson,et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain , 2006, Annals of neurology.
[41] A. Pisani,et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice , 2009, Proceedings of the National Academy of Sciences.
[42] J. Buxbaum,et al. Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson's Disease Mutation G2019S , 2010, The Journal of Neuroscience.
[43] R. Nichols,et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. , 2007, The Biochemical journal.
[44] Zilong Qiu,et al. A Calcium-Dependent Switch in a CREST-BRG1 Complex Regulates Activity-Dependent Gene Expression , 2008, Neuron.
[45] M. Beal,et al. Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine) , 2009, The Journal of Neuroscience.
[46] J. McCaffery,et al. Localization of GTPases by indirect immunofluorescence and immunoelectron microscopy. , 1995, Methods in enzymology.
[47] C. Chu,et al. Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells , 2008, Journal of neurochemistry.
[48] H. Cai,et al. Phosphorylation of Ezrin/Radixin/Moesin Proteins by LRRK2 Promotes the Rearrangement of Actin Cytoskeleton in Neuronal Morphogenesis , 2009, The Journal of Neuroscience.
[49] S. Wang,et al. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. , 2004, Gene therapy.
[50] P. Pollak,et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. , 2006, The New England journal of medicine.
[51] Nicholas W Wood,et al. A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.
[52] A. Gitler,et al. GTPase Activity Plays a Key Role in the Pathobiology of LRRK2 , 2010, PLoS genetics.
[53] P. Bickford,et al. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson’s disease , 2008, Neuroscience.
[54] L. Mucke,et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.
[55] Mark J. West,et al. New stereological methods for counting neurons , 1993, Neurobiology of Aging.
[56] Z. Wszolek,et al. PARK8 LRRK2 parkinsonism , 2006, Current neurology and neuroscience reports.
[57] David I. Bass,et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice , 2010, Neurobiology of Disease.
[58] Tatiana Foroud,et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease , 2005, The Lancet.
[59] A. Abeliovich,et al. The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology , 2006, Neuron.
[60] Shu Wang,et al. CMV enhancer/human PDGF-β promoter for neuron-specific transgene expression , 2004 .
[61] D. Moore. The biology and pathobiology of LRRK2: implications for Parkinson's disease. , 2008, Parkinsonism & related disorders.
[62] R. Bodmer,et al. Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons , 2008, Molecular Neurodegeneration.